IDO expression has a controversial impact in the TME with higher IDO expression correlated with a decrease in tumor growth and longer survival in patients with prostate cancer [335], hepatocellular carcinoma [336] and renal cell carcinoma [337]. Here, IDO1 is linked to Familial prostate cancer.